-
AstraZeneca history
- AstraZeneca milestones 1910-1980
- AstraZeneca Milestones 1981-2000
- AstraZeneca Milestones 2001-Present
- Corporate Evolution
AstraZeneca milestones 1981-2000
1981 TENORMIN® (atenolol) is introduced, a beta blocker for the treatment of hypertension.
1982 Just one year after being launched, TENORMIN becomes the #1 selling beta blocker in the US
Launch of PULMICORT® (budesonide), an anti-inflammatory corticosteroid for the treatment of asthma.
1983 Launch of RHINOCORT® (budesonide), made from the same active substance as PULMICORT, for the relief of symptoms caused by allergic rhinitis.
1984 Launch of TONOCARD® (tocainide HCI), the anti arrhythmic agent.
Launch of EMLA® (lidocaine 2.5% and prilocaine 2.5%) Cream, a topical anesthetic used primarily to diminish or prevent pain in needle procedures.
1989 Launch of PRILOSEC® (omeprazole), the proton pump inhibitor.
Introduction of DIPRIVAN® (propofol), the first I.V.-injectable emulsion, non-inhalant anesthetic for induction and maintenance.
1992 Launch of TOPROL XL® (metoprolol succinate) in the United States for the treatment of hypertension and angina.
1993 Launch of topical anesthetic EMLA Cream.
1994 Launch of RHINOCORT Nasal Inhaler.
1995 Launch of CASODEX® (bicalutamide), an antiandrogen for prostate cancer.
1998 Launch of ATACAND® (candesartan cilexetil), an angiotensin II receptor blocker for the treatment of hypertension.
CASODEX, becomes the most prescribed antiandrogen in the world.
ZOLADEX® (goserelin acetate implant) becomes the only LHRH agonist with FDA approval for early-stage prostate cancer.
ZESTRIL® (lisinopril) becomes the most prescribed ACE inhibitor in the US.
NOLVADEX® (tamoxifen citrate) is indicated to reduce the risk of breast cancer in women at high risk.
2000 ATACAND HCT® (candesartan cilexetil-hydrochlorothiazide) a second-line treatment for hypertension, receives FDA approval.
PULMICORT RESPULES® (budesonide inhalation suspension), for the control of persistent asthma in children as young as 12 months, receives FDA approval.
The FDA approves a new indication for ARIMIDEX® (anastrozole) for first-line treatment of advanced breast cancer in postmenopausal women.
